Despite Inflationary Headwinds, Chinese CRO WuXi PharmaTech Set To Ride Wave Of Global Outsourcing

BEIJING - Leading Chinese contract research organization WuXi PharmaTech will face inflationary pressure on profits this year, but stepped-up outsourcing of research to China by international pharmaceutical players and the Shanghai-based firm's expanding range of services are likely to ensure strong earnings through 2011 and beyond, according to a prominent analyst who monitors the country's healthcare sector